Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience


AYGEN B. , DEMİRTÜRK N., YILDIZ O. , ÇELEN M. K. , Celik I., Barut S., ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.31, ss.305-317, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 31 Konu: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/tjg.2020.19197
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Sayfa Sayıları: ss.305-317

Özet

Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) +/- dasabuvir (DSV) +/- ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r +/- DSV +/- RBV combination regimen in a real-world clinical practice.